NewCelX Ltd. (NCEL) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.1x

Market Cap

$17.79M

MomentumView details →

1D Return

−2.23%

YTD Return

+75.00%

RSI (14)

47.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.1x

Market Cap

$17.79M

RSI (14)

47.8

MomentumView details →

1D Return

−2.23%

YTD Return

+75.00%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

29.31%

ROA (TTM)

18.57%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+67.39%

FCF YoY

+51.41%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+91.79%

EBITDA YoY

+8.84%

EarningsView details →

EPS (Actual)

−$0.53

EPS Surprise

0.00%

Beats (12Q)

4/12

Next Q EPS Est

—

Avg Surprise (4Q)

73.48%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

0.76x

Quick Ratio

0.76x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

144065.00

Op. CF (TTM)

−6.34M

Next earningsMar 3, 2027 →

Latest newsMore news →

NewcelX priced a $1.4 million private equity financing at a 20% premium to support its lead Type 1 Diabetes program.43d ago

Similar companies

Pasithea Therapeutics Corp.KTTA Sensei Biotherapeutics, Inc.SNSE Lipocine Inc.LPCN Enlivex Therapeutics Ltd.ENLV Chemomab Therapeutics Ltd.CMMB VYNE Therapeutics Inc.VYNE Find similar companies →

Latest newsMore news →

NewcelX priced a $1.4 million private equity financing at a 20% premium to support its lead Type 1 Diabetes program.43d ago